Risk profiling for a refractory course of rheumatoid arthritis

Seminars in Arthritis and Rheumatism

Volumn 49, Issue 2, 2019, Pages 211-217

  Bécède, Manuel ^a   Alasti, Farideh ^a   Gessl, Irina ^a   Haupt, Lukas ^b   Kerschbaumer, Andreas ^a   Landesmann, Uriel ^a   Loiskandl, Michaela ^a   Supp, Gabriela M ^a   Smolen, Josef S ^a,b   Aletaha, Daniel ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b Hietzing Hospital   (Austria)

Author keywords

Outcome; Predictors; Refractory; Rheumatoid arthritis; Time to treatment

Indexed keywords

DISEASE MODIFYING ANTIRHEUMATIC DRUG; ANTIRHEUMATIC AGENT;

ADULT; ARTICLE; CASE CONTROL STUDY; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ACTIVITY; DRUG EFFICACY; DRUG RESPONSE; FEMALE; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OUTCOME ASSESSMENT; PREDICTIVE VALUE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; RISK FACTOR; SEX DIFFERENCE; THERAPY DELAY; AGED; FACTUAL DATABASE; PROGNOSIS; SEVERITY OF ILLNESS INDEX; SEX FACTOR; TIME TO TREATMENT;

ADULT; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DATABASES, FACTUAL; FEMALE; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; RISK ASSESSMENT; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SEX FACTORS; TIME-TO-TREATMENT;

EID: 85061651793     PISSN: 00490172     EISSN: 1532866X     Source Type: Journal    
DOI: 10.1016/j.semarthrit.2019.02.004     Document Type: Article

References (30)

1. Smolen, J.S., Aletaha, D., Bijlsma, J.W., Breedveld, F.C., Boumpas, D., Burmester, G., et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 69:4 (2010), 631–637.
2. Aletaha, D., Alasti, F., Smolen, J.S., Optimisation of a treat-to-target approach in rheumatoid arthritis: strategies for the 3-month time point. Ann Rheum Dis 75:8 (2016), 1479–1485.
3. Smolen, J.S., Landewe, R., Bijlsma, J., Burmester, G., Chatzidionysiou, K., Dougados, M., et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis 76:6 (2017), 960–977.
4. Singh, J.A., Saag, K.G., Bridges, S.L. Jr., Akl, E.A., Bannuru, R.R., Sullivan, M.C., et al. 2015 American College of Rheumatology Guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol. 68:1 (2016), 1–26.
5. Rahman, M.U., Buchanan, J., Doyle, M.K., Hsia, E.C., Gathany, T., Parasuraman, S., et al. Changes in patient characteristics in anti-tumour necrosis factor clinical trials for rheumatoid arthritis: results of an analysis of the literature over the past 16 years. Ann Rheum Dis 70:9 (2011), 1631–1640.
6. Smolen, J.S., Aletaha, D., McInnes, I.B., Rheumatoid arthritis. Lancet 388:10055 (2016), 2023–2038.
7. Mierau, M., Schoels, M., Gonda, G., Fuchs, J., Aletaha, D., Smolen, J.S., Assessing remission in clinical practice. Rheumatology(Oxford) 46:6 (2007), 975–979.
8. Aletaha, D., Funovits, J., Keystone, E.C., Smolen, J.S., Disease activity early in the course of treatment predicts response to therapy after one year in rheumatoid arthritis patients. Arthritis Rheum 56:10 (2007), 3226–3235.
9. Aletaha, D., Alasti, F., Smolen, J.S., Rheumatoid factor determines structural progression of rheumatoid arthritis dependent and independent of disease activity. Ann Rheum Dis 72:6 (2013), 875–880.
10. Gossec, L., Dougados, M., Goupille, P., Cantagrel, A., Sibilia, J., Meyer, O., et al. Prognostic factors for remission in early rheumatoid arthritis: a multiparameter prospective study. Ann Rheum Dis 63:6 (2004), 675–680.
11. Quinn, M.A., Emery, P., Window of opportunity in early rheumatoid arthritis: possibility of altering the disease process with early intervention. Clin Exp Rheumatol 21:5 Suppl 31 (2003), S154–S1S7.
12. Smolen, J.S., Aletaha, D., Machold, K.P., Therapeutic strategies in early rheumatoid arthritis. Best Pract Res Clin Rheumatol 19 (2005), 163–177.
13. Machold, K.P., Landewe, R., Smolen, J.S., Stamm, T.A., van der Heijde, D.M., Verpoort, K.N., et al. The stop arthritis very early (SAVE) trial, an international multicentre, randomised, double-blind, placebo-controlled trial on glucocorticoids in very early arthritis. Ann Rheum Dis 69:3 (2010), 495–502.
14. van Aken, J., Heimans, L., Gillet-van Dongen, H., Visser, K., Ronday, H.K., Speyer, I., et al. Five-year outcomes of probable rheumatoid arthritis treated with methotrexate or placebo during the first year (the PROMPT study). Ann Rheum Dis 73:2 (2014), 396–400.
15. Gerlag, D.M.S.M., Maijer, K.I., Tas, S.W., Starmans-Kool, M., van Tubergen, A., Janssen, M., Tak, P.P., Prevention of rheumatoid arthritis by B cell directed therapy in the earliest phase of the disease: the PRAIRI study [abstract]. Ann Rheum Dis, 75(Supplement 2), 2016, 125.
16. van der Heijde, D.M., Plain X-rays in rheumatoid arthritis: overview of scoring methods, their reliability and applicability. Bailliere's Clin Rheumatol 10:3 (1996), 435–453.
17. Arnett, F.C., Edworthy, S.M., Bloch, D.A., McShane, D.J., Fries, J.F., Cooper, N.S., et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31:3 (1988), 315–324.
18. Aletaha, D., Neogi, T., Silman, A.J., Funovits, J., Felson, D.T., Bingham, C.O. III, et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European league against rheumatism collaborative initiative. Arthritis Rheum. 62:9 (2010), 2569–2581.
19. Smolen, J.S., Breedveld, F.C., Schiff, M.H., Kalden, J.R., Emery, P., Eberl, G., et al. A simplified disease activity index for rheumatoid arthritis for use in clinical practice. Rheumatology (Oxford) 42:2 (2003), 244–257.
20. Vastesaeger, N., Xu, S., Aletaha, D., St Clair, E.W., Smolen, J.S., A pilot risk model for the prediction of rapid radiographic progression in rheumatoid arthritis. Rheumatology (Oxford) 48:9 (2009), 1114–1121.
21. Burmester, G.R., Blanco, R., Charles-Schoeman, C., Wollenhaupt, J., Zerbini, C., Benda, B., et al. Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial. Lancet 381:9865 (2013), 451–460.
22. Genovese, M.C., Kremer, J., Zamani, O., Ludivico, C., Krogulec, M., Xie, L., et al. Baricitinib in Patients with refractory rheumatoid arthritis. N Engl J Med 374:13 (2016), 1243–1252.
23. Aletaha, D., Bingham, C.O. 3rd, Tanaka, Y., Agarwal, P., Kurrasch, R., Tak, P.P., et al. Efficacy and safety of sirukumab in patients with active rheumatoid arthritis refractory to anti-TNF therapy (SIRROUND-T): a randomised, double-blind, placebo-controlled, parallel-group, multinational, phase 3 study. Lancet 389:10075 (2017), 1206–1217.
24. Smolen, J.S., Aletaha, D., Steiner, G., Does damage cause inflammation? Revisiting the link between joint damage and inflammation. Ann Rheum Dis 68:2 (2009), 159–162.
25. Winthrop, K.L., Strand, V., van der Heijde, D., Mease, P., Crow, M., Weinblatt, M., et al. The unmet need in rheumatology: reports from the targeted therapies meeting 2017. Clin Immunol 186 (2018), 87–93.
26. Roodenrijs, N.M.T., de Hair, M.J.H., van der Goes, M.C., Jacobs, J.W.G., Welsing, P.M.J., van der Heijde, D., et al. Characteristics of difficult-to-treat rheumatoid arthritis: results of an international survey. Ann Rheum Dis 77:12 (2018), 1705–1709.
27. Kearsley-Fleet, L., Davies, R., De Cock, D., Watson, K.D., Lunt, M., Buch, M.H., et al. Biologic refractory disease in rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. Ann Rheum Dis 77:10 (2018), 1405–1412.
28. Saevarsdottir, S., Wallin, H., Seddighzadeh, M., Ernestam, S., Geborek, P., Petersson, I.F., et al. Predictors of response to methotrexate in early DMARD naive rheumatoid arthritis: results from the initial open-label phase of the SWEFOT trial. Ann Rheum Dis 70:3 (2011), 469–475.
29. Nell, V., Machold, K.P., Eberl, G., Stamm, T.A., Uffmann, M., Smolen, J.S., Benefit of very early referral and very early therapy with disease-modifying anti-rheumatic drugs in patients with early rheumatoid arthritis. Rheumatology (Oxford) 43 (2004), 906–914 Epub 2004 Apr 27.
30. Lard, L.R., Visser, H., Speyer, I., vander Horst-Bruinsma, I.E., Zwinderman, A.H., Breedveld, F.C., et al. Early versus delayed treatment in patients with recent-onset rheumatoid arthritis: comparison of two cohorts who received different treatment strategies. Am J Med 111:6 (2001), 446–451.